The Therakind Team

Therakind’s highly focused senior team brings together a wealth of experience in drug formulation, drug delivery, clinical, commercial and regulatory strategy, project management, clinical study design, management, analysis and reporting, and securing agreements for Paediatric Investigation Plans (PIPs) and approvals for clinical trial and marketing authorisations.

Therakind’s senior team has a long record of effectively working together in previous companies over the last 20 years to deliver successful outcomes.

Chief Executive Officer* Dr Susan Conroy PhD
  • Dr Susan Conroy has been a director in Therakind since its inception.
  • She is an experienced pharmaceutical manager with over 15 years in the sector, specialising in the identification, evaluation, management and commercialisation of pharmaceutical and biotechnology projects.
  • As Chief Executive of Therakind, Susan leads the company’s strategy, identifying and negotiating key agreements and commercial opportunities as well as leading the day-to-day operations of the company. She brings the execution skills and discipline required to develop Therakind’s commercial potential, ensuring that trials and other milestone events are completed on time and budget.
  • With a PhD in Molecular Biology and post-doctoral research in oncology at University College London, Susan moved into industry.
  • Following several years of clinical trial work she moved into evaluating and commercialising potential and existing research/development projects in multiple pharmaceutical areas.
  • She then became a self-employed consultant specialising in maximising scientific value to early start up programmes and an independent funding assessor of university start-up projects, prior to establishing Therakind.
  • She has also worked as a consultant covering technology transfer, medical affairs and commercial exploitation of existing products.
Regulatory Affairs Director* Ms Jackie Winslade MTOPRA
  • Jackie has some 30 years experience in the pharmaceutical industry including 25 years in regulatory affairs
  • She worked for 10 years in the Global Regulatory Affairs Department of a major multinational pharmaceutical company, where she was responsible for worldwide product registration, before moving to work for smaller pharmaceutical companies.
  • Jackie is experienced in defining worldwide regulatory strategy, product development planning, coordinating and directing the preparation and review of worldwide regulatory submissions and establishing effective working relationships both within and outside the company
  • She has considerable knowledge of EU/US licensing procedures and pharmaceutical regulations, directives and guidelines including those relating to paediatrics
  • Her extensive experience covers a large number of therapeutic areas and all stages of product development
  • Jackie has worked for Therakind since 2007

 

Programme Director Ms Louise Rawcliffe BSc MBA
  • Louise has over 20 years’ experience in the pharmaceutical industry within regulatory affairs and regulatory compliance.
  • She has considerable knowledge of EU/US clinical trial regulations as well as medical device licensing procedures and regulations, directives and guidelines.
  • She has experience in managing compliance programmes for global clinical trials.
  • Louise has facilitated regulatory authority inspections of both UK- and US-based investigator sites and GMP and device manufacturing facilities.
  • Her extensive experience covers all phases of clinical development.
  • Louise also has 10 years’ experience in pharmacovigilance for licensed and investigational medicinal products.

 

Head of Pharmaceutical Development Dr Julie-Ann Penton PhD
  • Julie-Ann has over 18 years’ experience in the pharmaceutical industry working in pharmaceutical development and project management roles. She initially entered the pharmaceutical industry as a formulation development scientist for Rhone Poulenc Rorer (now Sanofi Aventis) before moving to Innovata Biomed (now Vectura) where she eventually became Director of Pharmaceutical Development and was responsible for both early phase and late phase pharmaceutical development projects.
  • Julie-Ann has extensive experience of managing all aspects of pharmaceutical development and has specific expertise in outsourcing and managing these activities at contract organisations. She also has specific expertise in writing and compiling the CMC components of regulatory packages and has significant experience with EU, US, and Japanese programmes. She has also acted as a pharmaceutical expert for a number of EU submissions.
  • Julie-Ann has also held roles in project management including the role of Projects Director at Vectura where she was responsible for the overall delivery of both early and late phase/commercialisation projects from cross functional project teams.
  • Julie-Ann has a degree in Pharmacy and holds a PhD in pharmaceutical drug delivery from the University of Manchester.
  • Since 2014 Julie-Ann has taken on the role of Head of Pharmaceutical Development for Therakind Limited.
Financial Controller Ms Samantha Race MA (Cantab)
  • Samantha, a qualified Chartered Accountant with ‘Big 4’ training and a Cambridge University degree, is a highly motivated finance professional with both managerial and overseas experience.
  • She has a proven track record in both financial and management accounting and systems development; her wide experience having been gained both at a number of high profile clients as well as from her successful spell as a finance professional within the software industry.
  • Samantha is responsible for the financial management of Therakind, to include planning and forecasting, internal control, statutory and EU reporting and company secretarial duties.
  • She works closely with the CEO providing management and the Board of Directors with timely and accurate information that is critical to the decision-making process.
Non Executive Director* Professor David S Latchman MA PhD DSc FRCPath FRSA CBE
  • Professor David Latchman CBE is Master of Birkbeck College, University of London and Professor of Genetics at Birkbeck and University College, London.
  • Professor Latchman has a first class honours BA in Natural Sciences, specialising in Genetics, a PhD and a DSc and has published extensively in the field of Genetics and Molecular Biology
  • He was appointed to the Chair of Human Genetics at UCL and Dean of the Institute of Child Health in 1999
  • Professor Latchman has an impressive track record as a fund-raiser, raising over £9 million pounds whilst Dean at the Institute of Child Health
  • On the basis of patents developed by his laboratory and with his significant experience of the commercial exploitation of intellectual property, he obtained Venture Capital funding to found a Company (Bio Vex Ltd) which is currently conducting phase 3 clinical trials in cancer and has recently been acquired by Amgen Ltd.
  • Professor Latchman serves on a number of committees including:
    • Confederation of British Industry (CBI) London Council (member)
    • National DNA Database Ethics Group (Home Office)
    • London First Board (Member)
    • Universities UK Research Policy Network (member)
    • Westminster Academy Advisory Board (member)
    • Women and Children First (Patron)
  • Professor Latchman was awarded the CBE for services to higher education in the Queen's Birthday Honours in June 2010.
Non-executive Director* Mr Cengiz Tarhan
  • Having trained as an accountant, after a spell at University of London Cengiz joined the Royal Free Hospital School of Medicine (RFHSM) in 1989.  In 1993 he was appointed as Finance Director for RFHSM and then continued as Director of Financial and Business Affairs for the Medical School on its merger with UCL in 1998.  

  • Cengiz established Freemedic PLC (now UCL Business PLC (UCLB)) as the commercial arm of RFHSM in 1993 and formally transferred from his UCL role to the position of Managing Director for UCLB in 2004.  Over the years he has been involved in many licences and spin-outs including PolyMASC Pharmaceuticals PLC, one of the first university spin-outs to float on the AIM in 1995, Medic to Medic Ltd (creators of the Map of Medicine) which was sold to Informa PLC in 2005 and Stanmore Implants Worldwide Limited which was acquired by Abingworth and MDY Healthcare in February 2008.
  • Cengiz also acts as a Director for a number of UCLB’s spinout companies, including Pentraxin Therapeutics Limited, UCLB Medical Devices Limited and Bloomsbury BioSeed Fund as well as acting as advisor to a number of international technology transfer organisations and universities.
Non-Executive Director* Mr Harold Gittelmon BA (Hons) MBA
  • Harold Gittelmon has more than 20 years of experience in the private equity, banking and retail sectors within Europe and the US.
  • He has held several executive roles in his career beginning with 3i Group plc, where he was in charge of several successful acquisitions, IPOs and AIM listings generating outstanding returns for his team. He was also a co-founder and Managing Director of private equity firm Eclipse Investment Partners, where he transacted on a considerable number of private equity deals. He then went on to run Harding Retail Ltd as CEO, and was CEO Europe for Flemingo thereafter.
  • Harold has considerable experience working with both small and large companies. He holds an MBA from Cass Business School and holds a BA (Hons) in Banking, Insurance and Finance from the University of Wales.
Non-Executive Director, Founder* Professor Ian Wong BSc MSc PhD MRPharmS
  • Professor Wong is the Professor of Paediatric Medicines Research and the Director of the Centre for Paediatric Pharmacy Research at The School of Pharmacy in London
  • He is a qualified pharmacist and worked at the former UK Medicines Control Agency before starting his research career in medication safety
  • Professor Wong took up a research pharmacist post at the David Lewis Centre for Epilepsy to investigate the safety of new anti-epileptic drugs between 1994 and 1997 and was awarded his PhD from Manchester Medical School
  • In 1997, Professor Wong was appointed as a lecturer at the University of Bradford before moving to The School of Pharmacy, University of London, to set up the Centre for Paediatric Pharmacy Research
  • He was awarded a Department of Health Public Health Career Scientist Award in 2002
  • Professor Wong and his colleagues also received the Neonatal and Paediatric Pharmacists Group Award in 2003 and Chemists and Druggists Pharmacy Practice Research Medal 2004 for his research in paediatric medicines
  • To date he has published over 200 publications